Posts Archive

NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex

NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM

NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)

NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)

NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05461209: Phase 3: Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

National Cancer Institute: Clinical Trials Information for Patients and Caregivers

Patient Education: Dexamethasaone (Decadron) and other Steroids

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM

NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Patient Education: Selinexor (Xpovio) - XPO1 inhibitor

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma

NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM